Elapsed time from breast cancer detection to first adjuvant therapy in a Canadian province, 1999-2000

CMAJ. Canadian Medical Association Journal

Volumn 170, Issue 6, 2004, Pages 957-961

  Rayson, Daniel ^a   Chiasson, Darrell ^a   Dewar, Ron ^b  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b Cancer Care Nova Scotia   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANADA; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; DISEASE SEVERITY; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL DOCUMENTATION; MEDICAL RECORD; NONBIOLOGICAL MODEL; PATIENT CARE; REGRESSION ANALYSIS; TIME;

EID: 1642374284     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1020972     Document Type: Article

References (17)

1. Mayo NE, Scott SC, Shen N, Hanley J, Goldberg MS, MacDonald N. Waiting time for breast cancer surgery in Quebec. CMAJ 2001;164(8):1133-8.
2. Olivotto IA, Bancej C, Goel V, Snider J, McAuley RG, Irvine B, et al. Waiting times from abnormal breast screen to diagnosis in 7 Canadian provinces. CMAJ 2001;165(3):277-83.
3. Simunovic M, Gagliardi A, McCready D, Coates A, Levine M, DePetrillo D. A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario. CMAJ 2001;165(4):421-5.
4. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999;353:1119-26.
5. Sainsbury R, Johnston C, Haward B. Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet 1999;353:1132-5.
6. Arndt V, Sturmer T, Stegmaier C, Ziegler H, Becker A, Brenner H. Provider delay among patients with breast cancer in Germany: a population-based study. J Clin Oncol 2003;21(8):1440-6.
7. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352(9132):930-42.
8. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351(9114):1451- 67.
9. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000;355(9217):1757- 70.
10. Waiting for a diagnosis after an abnormal breast screen in Canada. Report of the Working Group on the Integration of Screening and Diagnosis for the Canadian Breast Cancer Screening Initiative. Ottawa: Canadian Breast Cancer Screening Initiative Working Group on the Integration of Screening and Diagnosis; 2000. Cat no H39-526/2000E. Available: www.hc-sc.gc.ca/hppb/ahi/ breastcancer /pubs/diagnosis-report_eng.pdf (accessed 2002 Apr 15).
11. Whelan T, Olivotto I, Levine M, for the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: breast radiotherapy after breast-conserving surgery (summary of the 2003 update). CMAJ 2003;168(4):437-9.
12. Levine M, for the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-positive breast cancer (summary of the 2001 update). CMAJ 2001;164(5):644-6.
13. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997;15:1385-94.
14. Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK, et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten year analysis - an intergroup study. J Clin Oncol 1998;16:3486-92.
15. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, AbuZahra, et al. Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998;16:2651-8.
16. Risberg T, Sorbye SW, Norum J, Wist EA. Diagnostic delay causes more psychological distress in female than in male cancer patients. Anticancer Res 1996;16(2):995-9.
17. Thorne SE, Harris SR, Hislop TG, Vestrup JA. The experience of waiting for diagnosis after an abnormal mammogram. Breast J 1999;5(1):42-51.